Semaglutide Oral Research Tablets

This product presents semaglutide — a 31-residue, fatty-acid-modified analogue that activates the GLP-1 receptor — as a solid tablet for oral research instead of a freeze-dried vial. Nothing about the peptide changes: it has the identical CAS number and formula, an Aib residue in position 2 and a gamma-Glu-(AEEA)2-C18 diacid attached to Lys26. Everything around it is different, though. Stomach acid and pepsin would normally destroy a peptide of this size, and little of it would cross the gut lining, so the tablet includes an SNAC-type permeation enhancer (salcaprozate sodium) that briefly raises the local pH and helps the peptide pass through and between the cells of the epithelium.

Two related listings define what this tablet is for. The freeze-dried semaglutide vial offers the same molecule when you want to choose concentration and route yourself; orforglipron, a GLP-1 receptor agonist that isn't a peptide, is taken by mouth without any enhancer. The tablet sits between them and serves formulation research — how it dissolves, how concentrated the enhancer becomes at the lining of the gut and for how long, and why absorption varies so much for oral peptides that depend on an enhancer. Tablets come in 3 mg and 7 mg strengths, thirty per bottle; keep the bottle sealed at room temperature with the desiccant in it, because moisture changes how the tablet breaks up and how the enhancer behaves, not only the peptide.